Sail open-label extension of inhaled pirfenidone for IPF and PPF

Phase 2, open-label, single-arm trial of pirfenidone in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF), sponsored by Avalyn Pharmaceuticals. Primary endpoints: Incidence of treatment-emergent adverse events and serious adverse events, Incidence of adverse events of special interest and 4 more. Planned start Jul 2025; status: authorised.